

**Cell Reports, Volume 43**

**Supplemental information**

**Selective targeting of mu opioid receptors  
to primary cilia**

**Rita R. Fagan, David F. Lee, Matan Geron, Grégory Scherrer, Mark von Zastrow, and Aliza  
T. Ehrlich**

**Table S1:** Primers used for DNA construct molecular cloning.

| Construct                 | Forward Primer 1                                   | Reverse Primer 1  | Forward Primer 2                       | Reverse Primer 2                                    |
|---------------------------|--|---|--|---|
| MOR                       | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | TCTAGAGTCGCGGCCTCAAGG<br>CAGGGGGGCTG                              | N/A                                    | N/A   |
| MOR+linker                | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | TCTAGAGTCGCGGCCTCAGGT<br>AGCAATAGAGCCAGGC                         | N/A                                    | N/A   |
| MOR-Venus                 | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | TCTAGAGTCGCGGCCTTACTTA<br>TACAGCTCGTCCATGCC                       | N/A                                    | N/A   |
| MOR+5A                    | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | TCTAGAGTCGCGGCCTCAAGC<br>AGCAGCAGCAGCAGGCAGGG                     | N/A                                    | N/A   |
| DOR                       | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | TCTAGAGTCGCGGCCTCAGGC<br>GGCAGCGC                                 | N/A                                    | N/A   |
| DOR+linker                | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | GCGGCCTCAGGTAGCAATAGA<br>GCCGGCGGCAGC                             | N/A                                    | N/A   |
| KOR                       | GCTGGAGCAGCGGC<br>CATGGAGTCCCCCAT<br>TCAGATCTTC    | TCTAGAGTCGCGGCCTCATAC<br>TGGCTTATTCATCCCTCCAC                     | N/A                                    | N/A   |
| KOR+linker                | GCTGGAGCAGCGGC<br>CATGGAGTCCCCCAT<br>TCAGATCTTC    | GCGGCCTCAGGTAGCAATAGA<br>GCCTACTGGCTT                             | N/A                                    | N/A   |
| MOR(DOR-<br>ICL3)+linker  | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | TGATCTAGAGTCGCGGCCTCA<br>GGTAGCAATAGAGCCAGGC                      | N/A                                    | N/A   |
| MOR(DOR-<br>Ctail)+linker | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | GCGGCCTCAGGTAGCAATAGA<br>GCCGGCGGCAGC                             | N/A                                    | N/A   |
| DOR(MOR-<br>ICL3)+linker  | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | GCGGCCTCAGGTAGCAATAGA<br>GCCGGCGGCAGC                             | N/A                                    | N/A   |
| DOR(MOR-<br>Ctail)+linker | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | TCTAGAGTCGCGGCCTCAGGT<br>AGCAATAGAGCCAGGC                         | N/A                                    | N/A   |
| MOR(381T)+linker          | ACGCCGCTGGAGCA<br>GCGGCCATGGATAG<br>CTCTGCCGGCCCTG | AGTCGCGGCCTCAGGTAGCAA<br>TAGAGCCGTCCACGGTGT                       | N/A                                    | N/A   |
| DOR+MOR3+linker           | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | TCTAGAGTCGCGGCCTCAGGT<br>AGCAATAGAGCCAGGCAGGG<br>GGGCGGCAGCGCCACC | N/A                                    | N/A   |
| DOR+MOR5+linker           | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | AGAGTCGCGGCCTCAGGTAG<br>CAATAGAGCCAGGCAGGGGG<br>GCTGTGGCGGCAGCGCC | N/A                                    | N/A   |
| DOR+MOR12+linker          | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | TTCCAGGTTTTCCAGGGCGGC<br>AGCGCCACC                                | GGTGGCGCTGCCGC<br>CCTGGAAAACCTGG<br>AA | TCTAGAGTCGCGGCCTCAGG<br>TAGCAATAGAGCCAGGC           |
| DOR+MOR17+linker          | GCTGGAGCAGCGGC<br>CATGGAGCTGGTGC<br>CCT            | CTGGTGGTTGGTCTGGCGG<br>CAGCGCCACC                                 | GGTGGCGCTGCCGC<br>CAGGACCAACCACC<br>AG | TCTAGAGTCGCGGCCTCAGG<br>TAGCAATAGAGCCAGGC           |
| TULP3-eGFP                | GAAGATCTTGCGGC<br>CGAGGCGGCGCGC                    | TCTAGAGTCGCGGCCGCTCAT<br>TCACACGCCAGCTTG                          | TTTTGGCAAAGAATT<br>CATGGAGGCGGCGC      | CACCATGGTGAATTACTACC<br>TGATCCACTACCTTCACACGC<br>CA |
| TULP3(201T)-eGFP          | GAAGATCTTGCGGC<br>CGAGGCGGCGCGC                    | TCTAGAGTCGCGGCCTCATCC<br>AAGCTGGGCGTAC                            | TTTTGGCAAAGAATT<br>CATGGAGGCGGCGC      | CACCATGGTGAATTACTACC<br>TGATCCACTACCTCCAAGCTG       |

**Table S2:** Experiment time-line and corresponding figures for endogenous MOR staining in primary habenula culture (related to **Figure 1** and **Figure S1**).

| Experiment Day | Antigen         | Primary                         | Secondary                     | False Positives               | Figure   |
|----------------|-----------------|---------------------------------|-------------------------------|-------------------------------|--|
| Day 1          | MOR             | Rb anti-MOR                     |                               |                               |  |
| Day 2 (am)     |                 |                                 | Anti-rb-488                   | None                          |  |
| Day 2 (pm)     | AC3             | Rb anti-AC3                     |                               |                               |  |
| Day 3          |                 |                                 | Anti-rb-647                   | 647 may detect MOR and AC3    | <b>Figure 1F,</b><br><b>Control:</b><br><b>Figure S1D</b>  |
| <i>or</i>      |                 |                                 |                               |                               |  |
| Day 2 (pm)     | ARL13B          | Rb anti-ARL13B                  |                               |                               |  |
| Day 3          |                 |                                 | Anti-rb-647                   | 647 may detect MOR and ARL13B | <b>Figure 1F,</b><br><b>Control:</b><br><b>Figure S1E</b>  |
| <i>or</i>      |                 |                                 |                               |                               |  |
| Day 2 (pm)     | ARL13B          | Rb anti-ARL13B-647              | None                          | None                          | <b>Figure S1F,</b><br><b>Control:</b><br><b>Figure S1G</b> |
| <i>or</i>      |                 |                                 |                               |                               |  |
| Day 1          | MOR +<br>AC3    | Rb anti-MOR +<br>Chk anti-AC3   |                               |                               |  |
|                | MOR +<br>ARL13B | Rb anti-MOR +<br>Ms anti-ARL13B |                               |                               |  |
| Day 2          | MOR +<br>AC3    |                                 | Anti-rb-488 +<br>Anti-chk-647 | None                          | <b>Figure</b><br><b>S1H, top</b>                           |
|                | MOR +<br>ARL13B |                                 | Anti-rb-488 +<br>Anti-ms-647  | None                          | <b>Figure</b><br><b>S1H,</b><br><b>bottom</b>              |

Figure S1.





Figure S1. MOR-Venus cilia localization across multiple brain regions, MOR-mCherry localization to DRG primary cilia and wild-type MOR ciliary localization

**quantification.** MOR-Venus was amplified using a GFP antibody. **(A)** Schematic summary of brain regions with MOR-Venus localized to primary cilia: cortex (CTX), septum (Sep), dorsal striatum (DS), nucleus accumbens (ACB), medial habenula (mHb), paraventricular nucleus of the thalamus (PVT), and lateral hypothalamus (LH). Weak, undetectable cilia localization (small circles); strong, frequent ciliary localization (large circles). **(B)** Representative confocal micrographs depicting ciliary localized MOR-Venus in the DS (top panels) and mHb (bottom panels). Scale bars: 5 $\mu$ m. **(C)** Representative confocal micrograph of dorsal root ganglion (DRG) sections from 4-week old MOR-mCherry animals. mCherry signal was amplified using an mCherry antibody and cilia were identified using AC3 antibody. Scale bar: 20 $\mu$ m. **(C')** Example of an mCherry-positive cell with receptor localized to primary cilium, **(C'')** is an example of an mCherry-positive cell that does not have receptor localized in the primary cilium. Scale bars: 5 $\mu$ m. **(D-G)** Control stainings for main text **Figure 1**. **(D-E)** Representative confocal images of E18 cultured rat habenula neurons stained with the following sequence: no 1 $^{\circ}$  antibody for native MOR, anti-rabbit Alexa Fluor 488, rabbit anti-AC3 **(D)** or rabbit anti-ARL13B **(E)**, and anti-rabbit Alexa Fluor 647 to control for aberrant detection of ciliary MOR in AC3(+) **(D)** and ARL13B(+) **(E)** cilia. **(F)** Representative confocal micrographs of endogenous MOR localized to ARL13B-647 labeled cilia in E18 cultured rat habenula neurons. Arrows indicate wild-type MOR(+) primary cilia. **(G)** Representative confocal images of E18 cultured rat habenula neurons stained with the following sequence: no 1 $^{\circ}$  antibody for MOR, anti-rabbit Alexa Fluor 488, and rabbit anti-ARL13B-647 conjugated antibody to control for aberrant detection of ciliary MOR in ARL13B(+) cilia. **(H)** Representative confocal images of E18 cultured rat habenula neurons stained with antibodies against MOR and AC3 (top) or MOR and ARL13B (bottom). Arrows indicate wild-type MOR(+) primary cilia. Scale bars **(D-H)**: 10 $\mu$ m (merge), 5 $\mu$ m (individual channels). **(I)** The percent of MOR-positive cells with MOR localized to cilia was quantified using both cilia markers. The percent of MOR(+) cilia was 95.7% using AC3 and 90.1% using ARL13B; data are represented as mean  $\pm$  SEM from 3 independent experiments, 75-103 neurons. Arrows indicate cilia-localized receptor.


Figure S2.



**Figure S2. Ciliary localization of MOR in IMCD3 cells depends on cytoplasmic tail modification of MOR, is not a consequence of surface expression and modifies the duration of MOR cAMP signaling.** (A) Representative confocal images of MOR(+) primary cilium. IMCD3 cells transiently expressing Flag-tagged MOR. Cilia were stained with anti-ARL13B antibody. Scale bars: 5µm. (B-D) Expression control for constructs

analyzed in main text **Figure 2**. **(B)** Schematics and representative micrographs of MOR, MOR+linker, and dopamine receptor type 1 (DRD1) transiently expressed in IMCD3 cells. Surface receptors were labeled with Flag M1 and cilia were stained with anti-ARL13B antibody. Asterisks indicate low receptor-expressing cells, arrow heads point out cells with medium receptor expression, and arrows indicate high receptor expression. Examples of receptor(-) cilia are indicated by white symbols and receptor(+) cilia are shown by yellow symbols. Scale bars: 25 $\mu$ m. **(C)** Flow cytometry analysis of IMCD3 cells transfected with empty vector, MOR-Venus, MOR, or MOR+linker indicate no significant difference between MOR and C-terminally tagged constructs. One-way ANOVA (\* $p=0.0107$ ) with Dunnett's multiple comparisons, data are represented as mean  $\pm$  SEM from 4 independent experiments. **(D)** Western blot depicting receptor expression levels of MOR-Venus, MOR, and MOR+linker expressed in IMCD3 cells. Equal protein was loaded into wells and blots were probed for Flag, GFP, and loading control GAPDH. **(E)** cAMP as measured by cADDis biosensor in IMCD3 cells transiently expressing MOR (left) or MOR+linker (right). Live cells were imaged for baseline fluorescence for one minute prior to drug treatment with either vehicle (grey), 1 $\mu$ M forskolin (FSK, blue), 1 $\mu$ M DAMGO (orange), or both DAMGO+FSK (green). Data are represented as mean  $\pm$  SEM from from independent experiments. **(F)** Summary data of the cAMP area under the curve (AUC, positive peaks). Two-way ANOVA interaction (ns)  $p=0.0995$ ; main effect of receptor (\*)  $p=0.0259$ ; main effect of drug (\*\*\*\*)  $p<0.0001$ . Sidak's multiple comparisons test, data are represented as mean  $\pm$  SEM from 4 independent experiments, 9-44 cells in each biological replicate, (\*)  $p=0.0114$ . Arrows indicate cilia-localized receptor.


Figure S3.





**Figure S3. The MOR C-tail is highly divergent from DOR C-tail and suffices to drive DOR cilia enrichment.** (A-B) Plasma membrane expression validation for constructs analyzed in main text **Figure 3**. (A) Wide view of IMCD3 cells transiently expressing MOR(DOR-ICL3)+linker or MOR(DOR-Ctail)+linker demonstrating plasma membrane expression of constructs analyzed in Figure 3. Scale bars: 20 $\mu$ m (top), 5 $\mu$ m (bottom). (B) Wider view of DOR(MOR-ICL3)+linker or DOR(MOR-Ctail)+linker expressing cells to indicate proper plasma membrane expression of mutant receptors analyzed. Scale bars: 20 $\mu$ m (top), 5 $\mu$ m (bottom). (C) Representative confocal images of IMCD3 cells transiently expressing the indicated DOR constructs and labeled as described in **Figure 3**. Scale bars: 5 $\mu$ m. (D) Cilia enrichment analysis of DOR, DOR+linker, DOR(MOR-ICL3)+linker, and DOR(MOR-Ctail)+linker indicates that the MOR C-tail significantly enhances DOR cilia enrichment compared to DOR. One-way ANOVA (\*\*\*\* $p < 0.0001$ ) with Dunnett's multiple comparisons, data are represented as mean  $\pm$  SEM from 3 independent experiments, 32-47 cells, (\*\*\*\*)  $p < 0.0001$ . Scale bars, 5 $\mu$ m. (E). Schematic of DOR+MOR constructs containing all of the DOR C-tail with progressive additions of the MOR C-tail. (F) Wider view of IMCD3 cells transiently transfected with DOR+MOR sufficiency as described in **Figure 3** demonstrating plasma membrane localization of all constructs. Arrows indicate cilia-localized receptor. Scale bars: 20 $\mu$ m (top), 5 $\mu$ m (bottom).

**Figure S4.**



**Figure S4. Comparison of staining techniques used in IMCD3 cells and additional TULP3-KO cell experiments supports a role of TULP3 in MOR cilia delivery.** (A) Schematic of different receptor and cilia staining methods: Left: surface-expressed receptors are labeled prior to permeabilization in order to detect only the receptors trafficked to the cilium and cell surface. Right: all receptors are detected using the permeabilization method, thereby decreasing the relative ciliary receptor fluorescence compared to the whole cell. (B) Representative images of IMCD3 cells transiently expression DRD1 or MOR+linker. Cells were surface labeled with anti-Flag and cilia were

stained with anti-ARL13B (surface-labeled), or permeabilized and stained with anti-Flag and anti-AcTub (permeabilized). Scale bars: 5 $\mu$ m. **(C)** Image analysis demonstrates the reduction of ciliary fold enrichment with the permeabilization method (compare **Figure 2** (surface-labeled) to **Figure 4** (permeabilized)). Two-way ANOVA interaction (ns)  $p=0.3$ ; main effect of receptor (ns)  $p=0.0638$ ; main effect of staining method (\*\*)  $p=0.0065$ . Sidak's multiple comparison's test, data are represented as mean  $\pm$  SEM from 3 independent experiments, 24-60 cells, (\*)  $p=0.0198$ . **(D)** Representative images of wildtype (left) and TULP3-KO #2<sup>1</sup> (right) IMCD3 cells transiently transfected with MOR+linker. Cells were fixed and stained with anti-Flag and anti-AcTub antibodies. Scale bars: 5 $\mu$ m. **(E)** MOR+linker cilia enrichment was significantly reduced in TULP3-KO #2 IMCD3 cells than in wildtype. Student's t test, (\*)  $p<0.038$ , data are represented as mean  $\pm$  SEM,  $n=4$  experiments, 77-79 cells. Scale bars, 5 $\mu$ m. **(F)** Western blot validation of TULP3 CRISPR/Cas9 knockout IMCD3 cell lines #1 (main text, **Figure 4**) and #2. Equal protein was loaded into wells and blot was probed for TULP3 and loading control ACTIN. Arrow indicates TULP3 protein band. Arrows indicate cilia-localized receptor.

## Supplemental References

1. Ye, F., Nager, A.R., and Nachury, M.V. (2018). BBSome trains remove activated GPCRs from cilia by enabling passage through the transition zone. *J Cell Biol* 217, 1847-1868. [10.1083/jcb.201709041](https://doi.org/10.1083/jcb.201709041).